Cargando…

Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App

BACKGROUND: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira-Azevedo, Nuno, Osório, Luís, Fraga, Avelino, Roobol, Monique J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367845/
https://www.ncbi.nlm.nih.gov/pubmed/28410180
http://dx.doi.org/10.2196/cancer.6750
_version_ 1782517845415952384
author Pereira-Azevedo, Nuno
Osório, Luís
Fraga, Avelino
Roobol, Monique J
author_facet Pereira-Azevedo, Nuno
Osório, Luís
Fraga, Avelino
Roobol, Monique J
author_sort Pereira-Azevedo, Nuno
collection PubMed
description BACKGROUND: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both practitioners and patients for a variety of purposes. OBJECTIVE: The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC). METHODS: The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow was established to ensure that depending on the available clinical information the most complete risk model of the RPCRC was used. The user interface was designed and then the app was developed as a native app for iOS. The usability of the app was assessed using the Post-Study System Usability Questionnaire (PSSUQ) developed by IBM, in a group of 92 participants comprising urologists, general practitioners, and medical students. RESULTS: A total of 11 questions were built into the app, and, depending on the answers, one of the different algorithms of the RPCRC could be used to predict the risk of prostate cancer and of clinically significant prostate cancer (Gleason score ≥7 and clinical stage >T2b). The system usefulness, information quality, and interface quality scores were high—92% (27.7/30), 87% (26.2/30), and 89% (13.4/15), respectively. No usability problems were identified. CONCLUSIONS: The RPCRC app is helpful in predicting the risk of prostate cancer and, even more importantly, clinically significant prostate cancer. Its algorithms have been externally validated before and the usability score shows the app’s interface is well designed. Further usability testing is required in different populations to verify these results and ensure that it is easy to use, to warrant a broad appeal, and to provide better patient care.
format Online
Article
Text
id pubmed-5367845
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-53678452017-04-14 Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App Pereira-Azevedo, Nuno Osório, Luís Fraga, Avelino Roobol, Monique J JMIR Cancer Original Paper BACKGROUND: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both practitioners and patients for a variety of purposes. OBJECTIVE: The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC). METHODS: The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow was established to ensure that depending on the available clinical information the most complete risk model of the RPCRC was used. The user interface was designed and then the app was developed as a native app for iOS. The usability of the app was assessed using the Post-Study System Usability Questionnaire (PSSUQ) developed by IBM, in a group of 92 participants comprising urologists, general practitioners, and medical students. RESULTS: A total of 11 questions were built into the app, and, depending on the answers, one of the different algorithms of the RPCRC could be used to predict the risk of prostate cancer and of clinically significant prostate cancer (Gleason score ≥7 and clinical stage >T2b). The system usefulness, information quality, and interface quality scores were high—92% (27.7/30), 87% (26.2/30), and 89% (13.4/15), respectively. No usability problems were identified. CONCLUSIONS: The RPCRC app is helpful in predicting the risk of prostate cancer and, even more importantly, clinically significant prostate cancer. Its algorithms have been externally validated before and the usability score shows the app’s interface is well designed. Further usability testing is required in different populations to verify these results and ensure that it is easy to use, to warrant a broad appeal, and to provide better patient care. JMIR Publications 2017-01-06 /pmc/articles/PMC5367845/ /pubmed/28410180 http://dx.doi.org/10.2196/cancer.6750 Text en ©Nuno Pereira-Azevedo, Luís Osório, Avelino Fraga, Monique J Roobol. Originally published in JMIR Cancer (http://cancer.jmir.org), 06.01.2017. https://creativecommons.org/licenses/by/2.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/ (https://creativecommons.org/licenses/by/2.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on http://cancer.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Pereira-Azevedo, Nuno
Osório, Luís
Fraga, Avelino
Roobol, Monique J
Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title_full Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title_fullStr Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title_full_unstemmed Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title_short Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App
title_sort rotterdam prostate cancer risk calculator: development and usability testing of the mobile phone app
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367845/
https://www.ncbi.nlm.nih.gov/pubmed/28410180
http://dx.doi.org/10.2196/cancer.6750
work_keys_str_mv AT pereiraazevedonuno rotterdamprostatecancerriskcalculatordevelopmentandusabilitytestingofthemobilephoneapp
AT osorioluis rotterdamprostatecancerriskcalculatordevelopmentandusabilitytestingofthemobilephoneapp
AT fragaavelino rotterdamprostatecancerriskcalculatordevelopmentandusabilitytestingofthemobilephoneapp
AT roobolmoniquej rotterdamprostatecancerriskcalculatordevelopmentandusabilitytestingofthemobilephoneapp